Imren S - Search Results

1

Protease inhibitors: role and potential therapeutic use in human cancer.

DeClerck YA, Imren S. DeClerck YA, et al. Among authors: imren s. Eur J Cancer. 1994;30A(14):2170-80. doi: 10.1016/0959-8049(94)00460-m. Eur J Cancer. 1994. PMID: 7857719 Review.

2

Proteases and protease inhibitors in tumor progression.

DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE. DeClerck YA, et al. Among authors: imren s. Adv Exp Med Biol. 1997;425:89-97. doi: 10.1007/978-1-4615-5391-5_9. Adv Exp Med Biol. 1997. PMID: 9433492 Review.

3

Tissue inhibitors of matrix metalloproteinases in cancer.

Blavier L, Henriet P, Imren S, Declerck YA. Blavier L, et al. Among authors: imren s. Ann N Y Acad Sci. 1999 Jun 30;878:108-19. doi: 10.1111/j.1749-6632.1999.tb07677.x. Ann N Y Acad Sci. 1999. PMID: 10415723 Review.

4

Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion.

Imren S, Kohn DB, Shimada H, Blavier L, DeClerck YA. Imren S, et al. Cancer Res. 1996 Jul 1;56(13):2891-5. Cancer Res. 1996. PMID: 8674034

5

Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases.

Luo MP, Gomperts B, Imren S, DeClerck YA, Ito M, Velicescu M, Felix JC, Dubeau L. Luo MP, et al. Among authors: imren s. Gynecol Oncol. 1997 Dec;67(3):277-84. doi: 10.1006/gyno.1997.4880. Gynecol Oncol. 1997. PMID: 9441775

6

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study.

Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, Eidenschink Brodersen L, Pardo L, Cummings CL, Loeb KR, Le Q, Imren S, Leonti AR, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche TJ Jr, Nguyen C, Meerzaman D, Loken MR, Oehler VG, Bolouri H, Meshinchi S. Smith JL, et al. Among authors: imren s. Clin Cancer Res. 2020 Feb 1;26(3):726-737. doi: 10.1158/1078-0432.CCR-19-1800. Epub 2019 Nov 12. Clin Cancer Res. 2020. PMID: 31719049 Free PMC article.

7

Changes observed in the growth fraction, labeling index, duration of S phase, and total cell cycle times of HL-60 cells as they undergo differentiation in response to retinoic acid.

Gezer S, Yasin Z, Imren S, Freeman J, Black A, Raza A. Gezer S, et al. Among authors: imren s. Cancer Res. 1988 Nov 1;48(21):5989-94. Cancer Res. 1988. PMID: 2844395

8

Expression of nucleolar antigen p145 in bone marrow cells of patients with myeloid leukemias.

Raza A, Imren S, Gezer S, Verkh L, Freeman JW. Raza A, et al. Among authors: imren s. Cancer Res. 1989 Jan 15;49(2):482-7. Cancer Res. 1989. PMID: 2910466

9

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target.

Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, Hylkema TA, Castro S, Tang TT, McKay CN, Perkins L, Pardo L, Sarthy J, Beckman AK, Williams R, Idemmili R, Furlan S, Ishida T, Call L, Srivastava S, Loeb AM, Milano F, Imren S, Morris SM, Pakiam F, Olson JM, Loken MR, Brodersen L, Riddell SR, Tarlock K, Bernstein ID, Loeb KR, Meshinchi S. Le Q, et al. Among authors: imren s. J Clin Invest. 2022 Nov 15;132(22):e157101. doi: 10.1172/JCI157101. J Clin Invest. 2022. PMID: 36136600 Free PMC article.

10

Cell cycle characteristics in myeloid leukemias.

Raza A, Khan SP, Mehdi I, Imren S, Yasin Z, Preisler HD. Raza A, et al. Among authors: imren s. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:26-9. Bone Marrow Transplant. 1989. PMID: 2713557 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page